Leerink Partnrs Issues Negative Outlook for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Research analysts at Leerink Partnrs cut their Q3 2025 EPS estimates for shares of Arcturus Therapeutics in a note issued to investors on Thursday, October 23rd. Leerink Partnrs analyst L. Nsongo now anticipates that the biotechnology company will earn ($1.31) per share for the quarter, down from their previous forecast of ($0.64). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics’ Q4 2025 earnings at ($1.78) EPS, FY2025 earnings at ($3.95) EPS, FY2026 earnings at ($4.91) EPS, FY2027 earnings at ($5.86) EPS, FY2028 earnings at ($4.89) EPS and FY2029 earnings at ($4.50) EPS.

A number of other equities research analysts have also recently weighed in on the company. Citigroup cut Arcturus Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $49.00 to $12.00 in a research note on Thursday. Zacks Research upgraded Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. BTIG Research cut their price objective on shares of Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Guggenheim cut Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.71.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $11.22 on Monday. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $24.17. The firm has a market capitalization of $304.74 million, a PE ratio of -5.03 and a beta of 2.39. The stock’s fifty day moving average is $18.72 and its 200 day moving average is $14.83.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.The firm had revenue of $28.30 million during the quarter, compared to analysts’ expectations of $17.64 million.

Hedge Funds Weigh In On Arcturus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ARCT. Osaic Holdings Inc. raised its stake in Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares in the last quarter. US Bancorp DE raised its position in Arcturus Therapeutics by 218.9% in the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,329 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 2,586 shares during the period. Strs Ohio acquired a new stake in shares of Arcturus Therapeutics during the first quarter worth about $89,000. Finally, Russell Investments Group Ltd. raised its stake in Arcturus Therapeutics by 40,686.2% during the 1st quarter. Russell Investments Group Ltd. now owns 11,828 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 11,799 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.